Indivior CFO acquires 14,059 shares in merger
The merger provided no cash consideration apart from cash paid in lieu of a fractional share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Indivior Pharmaceuticals, Inc. (INDV) recorded Timothy C. Dec, SVP, Chief Financial Officer, acquiring 14,059 common shares on November 2, 2026, in the merger exchange. Each outstanding Supernus Pharmaceuticals common share was converted into the right to receive 1.5401 Indivior common shares. His options and restricted stock units were assumed and converted into corresponding awards, with substantially the same terms and vesting; exercise prices were adjusted using the exchange ratio.
Insider Trade Summary
Other: 552,511 shares
Other
18 txns
Insider
DEC TIMOTHY C
Role
SVP, Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Employee Stock Option (right to buy) F2, F3 | 130,908 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 38,502 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 61,604 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 77,005 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 61,604 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 26,951 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F4 | 3,850 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F5 | 9,240 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F6 | 5,197 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F7 | 4,620 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F8 | 107,807 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F9 | 1,925 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F10 | 1,925 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F10 | 1,925 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F9 | 1,886 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F10 | 1,886 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F11 | 1,617 | $0.00 | $0.00 |
| Other | Common Stock F1 | 14,059 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 396,574 contracts (Direct);
Restricted Stock Units — 141,878 contracts (Direct);
Common Stock — 14,059 shares (Direct)
Footnotes (11)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
- F2. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards were converted into time-vesting restricted stock units.
- F3. The option vests in four equal annual installments beginning on the specified date.
- F4. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
- F5. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
- F6. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
- F7. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
- F8. These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in four installments. 50% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 20% of the RSUs vest upon the three-year anniversary of the Closing.
- F9. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2027.
- F10. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2026.
- F11. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2028.
Key Figures
Common shares acquired: 14,059 shares
Common shares held after transaction: 14,059 shares
Converted option award exercise price: $16.30 per share
+2 more
5 metrics
Common shares acquired
14,059 shares
Merger exchange on November 2, 2026
Common shares held after transaction
14,059 shares
Direct holdings reported after the November 2, 2026 transaction
Converted option award exercise price
$16.30 per share
Option award covering 130,908 common shares
Converted option award exercise price
$20.91 per share
Option award covering 38,502 common shares
Restricted stock units
107,807 units
Converted award reported November 2, 2026
Key Terms
exchange ratio, Employee Stock Option (right to buy), Restricted Stock Units, time-vesting restricted stock units, +1 more
5 terms
exchange ratio technical
"multiplied by the 1.5401 exchange ratio"
The exchange ratio is the number used to decide how many shares of one company you get for each share you own in another company during a merger or acquisition. It’s like a recipe that tells you how to swap shares fairly, ensuring both companies’ values are balanced. This ratio matters because it determines how ownership divides between the companies' shareholders.
Employee Stock Option (right to buy) financial
"Employee Stock Option (right to buy)"
Restricted Stock Units financial
"These restricted stock units are settled in common stock upon vesting"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
time-vesting restricted stock units financial
"performance stock unit awards were converted into time-vesting restricted stock units"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How were INDV options and restricted stock units adjusted in the merger?
Outstanding equity awards were assumed and converted into corresponding awards covering a number of shares based on the 1.5401 exchange ratio, rounded down. Per-share exercise prices were divided by that ratio and rounded up to the nearest whole cent. Converted awards remained subject to substantially the same terms and conditions, including vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
